All In Biotech

Drug Trial Radar · NCT06977737

A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

A Phase 1-2 Master Protocol to Study Intravenous ATTR-01 in Adult Participants With Select Epithelial Solid Tumours Under Multiple Sub-protocols

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 21, 2025

Primary completion

Dec 31, 2029

Study completion Dec 31, 2034

Sponsor

Lead sponsor
Accession Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
May 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given to humans. If an optimal dose is identified, additional sub-protocols will be added by to further elicit whether ATTR-01 may successfully treat cancer. Expanded access is not available.

Conditions

  • Solid Tumor, Adult

Interventions

  • ATTR-01Drug

    Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. • Incidence of treatment emergent adverse events (AEs) [safety and tolerability]Time frame: 1 year, 2 years and 5 years
  2. • Determination of the optimal dose of ATTR-01Time frame: 1 year, 2 years and 5 years
  3. • Objective Response Rate (ORR) [Evaluation of the anti-tumour activity of ATTR-01 per RECIST V1.1]Time frame: 1 year, 2 years and 5 years
  4. Duration of Response (DoR) [Evaluation of the anti-tumour activity of ATTR-01 per RECIST V1.1]Time frame: 1 year, 2 years and 5 years

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • START Barcelona

    Barcelona, Spain · Recruiting

  • Start Fjd

    Madrid, Spain · Recruiting

  • Start Hm Ciocc

    Madrid, Spain · Recruiting

  • General Hospital San Pedro - START

    Rioja, Spain · Not yet recruiting

  • , St James' University Hospital

    Leeds, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, Scotland, United Kingdom · Recruiting

  • Velindre Cancer Centre

    Cardiff, Wales, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.